BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9209388)

  • 1. Two different bindings of p21 Cdk inhibitor to cyclin/Cdk complex.
    Nakanishi M; Kagawa Y; Takahashi H; Matsushime H
    Leukemia; 1997 Apr; 11 Suppl 3():356-7. PubMed ID: 9209388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression.
    Hiyama H; Iavarone A; LaBaer J; Reeves SA
    Oncogene; 1997 May; 14(21):2533-42. PubMed ID: 9191053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct interaction of p21 cyclin-dependent kinase inhibitor with the retinoblastoma tumor suppressor protein.
    Nakanishi M; Kaneko Y; Matsushime H; Ikeda K
    Biochem Biophys Res Commun; 1999 Sep; 263(1):35-40. PubMed ID: 10486249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solution structure of p21(Waf1/Cip1/Sdi1) C-terminal domain bound to Cdk4.
    Sung YH; Shin J; Shin J; Lee W
    J Biomol Struct Dyn; 2001 Dec; 19(3):419-27. PubMed ID: 11790141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of retinoblastoma protein phosphorylation by myogenesis-induced changes in the subunit composition of the cyclin-dependent kinase 4 complex.
    Wang J; Walsh K
    Cell Growth Differ; 1996 Nov; 7(11):1471-8. PubMed ID: 8930396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimerization of the amino terminal domain of p57Kip2 inhibits cyclin D1-cdk4 kinase activity.
    Reynaud EG; Guillier M; Leibovitch MP; Leibovitch SA
    Oncogene; 2000 Feb; 19(9):1147-52. PubMed ID: 10713702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nuclear protein p34SEI-1 regulates the kinase activity of cyclin-dependent kinase 4 in a concentration-dependent manner.
    Li J; Melvin WS; Tsai MD; Muscarella P
    Biochemistry; 2004 Apr; 43(14):4394-9. PubMed ID: 15065884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
    Fotedar R; Fitzgerald P; Rousselle T; Cannella D; Dorée M; Messier H; Fotedar A
    Oncogene; 1996 May; 12(10):2155-64. PubMed ID: 8668341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of cyclin-dependent kinase 4 during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1.
    Phelps DE; Xiong Y
    Cell Growth Differ; 1998 Aug; 9(8):595-610. PubMed ID: 9716177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
    Park H; Yeom MS; Lee S
    Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHK21 cells.
    Sekiguchi T; Hunter T
    Oncogene; 1998 Jan; 16(3):369-80. PubMed ID: 9467962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cdk4 activation is dependent on the subunit rearrangement in the complexes.
    Takahashi H; Menjo M; Kaneko Y; Ikeda K; Matsushime H; Nakanishi M
    Biochem Biophys Res Commun; 2000 Jan; 267(1):388-93. PubMed ID: 10623629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia.
    Said TK; Moraes RC; Singh U; Kittrell FS; Medina D
    Cell Growth Differ; 2001 Jun; 12(6):285-95. PubMed ID: 11432803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
    Coppock DL; Buffolino P; Kopman C; Nathanson L
    Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New functional activities for the p21 family of CDK inhibitors.
    LaBaer J; Garrett MD; Stevenson LF; Slingerland JM; Sandhu C; Chou HS; Fattaey A; Harlow E
    Genes Dev; 1997 Apr; 11(7):847-62. PubMed ID: 9106657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased G1 cyclin/cdk activity in cells overexpressing the candidate oncogene, MCT-1.
    Dierov J; Prosniak M; Gallia G; Gartenhaus RB
    J Cell Biochem; 1999 Sep; 74(4):544-50. PubMed ID: 10440924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of cdk4 and cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin-cdk complexes.
    Jaumot M; Estanyol JM; Serratosa J; Agell N; Bachs O
    Hepatology; 1999 Feb; 29(2):385-95. PubMed ID: 9918914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1.
    Benzeno S; Narla G; Allina J; Cheng GZ; Reeves HL; Banck MS; Odin JA; Diehl JA; Germain D; Friedman SL
    Cancer Res; 2004 Jun; 64(11):3885-91. PubMed ID: 15172998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immortalization of human fibroblasts by SV40 large T antigen results in the reduction of cyclin D1 expression and subunit association with proliferating cell nuclear antigen and Waf1.
    Peterson SR; Gadbois DM; Bradbury EM; Kraemer PM
    Cancer Res; 1995 Oct; 55(20):4651-7. PubMed ID: 7553644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
    Sweeney KJ; Swarbrick A; Sutherland RL; Musgrove EA
    Oncogene; 1998 Jun; 16(22):2865-78. PubMed ID: 9671407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.